Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

94.7%

+8.2% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

22%

4 of 18 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
14(73.7%)
Phase 2
4(21.1%)
Phase 3
1(5.3%)
19Total
Phase 1(14)
Phase 2(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT00528528Phase 2Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Role: lead

NCT00910806Phase 1Completed

TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

Role: lead

NCT00703118Phase 3Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Role: lead

NCT00580801Phase 2Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Role: lead

NCT00561015Phase 2Completed

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Role: lead

NCT00946842Phase 1Completed

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

Role: lead

NCT01012284Phase 1Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Role: lead

NCT00933283Phase 1Completed

A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Role: lead

NCT01291563Phase 1Completed

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Role: lead

NCT01391117Phase 1Terminated

TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

Role: lead

NCT01253551Phase 1Completed

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

Role: lead

NCT00523926Phase 2Completed

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

Role: lead

NCT00828529Phase 1Completed

TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer

Role: lead

NCT01275599Phase 1Completed

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Role: collaborator

NCT00828789Phase 1Completed

VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer

Role: lead

NCT00973388Phase 1Completed

VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Role: lead

NCT00903773Phase 1Completed

VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

Role: lead

NCT00933894Phase 1Completed

VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram

Role: lead

NCT00775125Phase 1Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Role: lead

All 19 trials loaded